Try Alerts Free   |   Login
Health Care › Surgical And Medical Instruments And Apparatus

ICUI Price Correlated With Financials For ICU Medical

Free historical financial statements for ICU Medical Inc.. See how revenue, income, cash flow, and balance sheet financials have changed over 53 quarters since 2009. Compare with ICUI stock chart to see long term trends.

ICUI Stock Compared to Quarterly

ICUI Income Statement

Revenue, Net:543122000
Revenue Per Share:22.7285
Cost of Goods & Services Sold:374295000
Gross Profit:168827000
Selling, General & Admin Expense:153212000
Research & Development Expense:23871000
Total Operating Expenses:210988000
Operating Income:-54801000
Income Taxes:-16733000
Net Income:-38068000
Earnings Per Share, Basic:-1.61
Shares Outstanding, Basic Avg:23896032

ICUI Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:53138000
Change in Accounts Receiveable:-22489000
Net Cash from Operations:-1342000
Net Cash from Operations Per Share:-0.0562
Net Cash from Financing Activities:1648917000
Property, Plant & Equipment Purchases:23606000
Purchases of Businesses, Net of Cash:1844164000
Net Cash from Investing Activities:-1867750000
Net Change in Cash & Equivalents:-223399000

ICUI Balance Sheet

Cash and Cash Equivalents:344292000
Accounts Receivable, Net:202897000
Total Current Assets:1173995000
Property, Plant & Equipment, Net:674412000
Total Assets:4746732000
Accounts Payable:200991000
Current Portion of Long-Term Debt:13813000
Total Short-Term Liabilities:494115000
Long Term Debt, Non-Current Portion:1642171000

Insider Trading

SEC Form 4
25,835 sh at $173

ICU Medical, Inc. ("ICU" or "we"), a Delaware corporation, operates in one business segment engaged in the development, manufacturing and sale of innovative medical devices used in infusion therapy and critical care applications. We are one of the world's leading pure-play infusion therapy companies with a wide-ranging product portfolio that includes IV solutions, IV smart pumps with pain management and safety software technology, dedicated and non-dedicated IV sets and needlefree connectors designed to help meet clinical, safety and workflow goals. We sell the majority of our products through our direct sales force and through independent distributors throughout the U.S. and internationally. Additionally, we sell our products on an original equipment manufacturer basis to other medical device manufacturers. The manufacturing for all product groups occurs in Salt Lake City, Utah, Austin, Texas, Mexico and Costa Rica.

All subsidiaries are wholly owned and are included in the consolidated financial statements.  All intercompany accounts and transactions have been eliminated. Results of operations of companies purchased are included from the dates of acquisition.

The consolidated financial statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation. These consolidated financial statements were prepared in accordance with accounting principles generally accepted in the U.S. ("GAAP"). Preparing financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash, Cash Equivalents

Cash equivalents are short-term, highly liquid investments that are readily convertible to known amounts of cash and have original maturities of three months or less from the date of purchase.

Accounts Receivable

Accounts receivable are stated at net realizable value.  An allowance is provided for estimated collection losses based on an assessment of various factors.  We consider prior payment trends, the age of the accounts receivable balances, financial status and other factors to estimate the cash which ultimately will be received.  Such amounts cannot be known with certainty at the financial statement date.  We regularly review individual past due balances for collectability.


Inventories are stated at the lower of cost or net realizable value with cost determined using the first-in, first-out method.  Inventory costs include material, labor and overhead related to the manufacturing of our products.

Inventories consist of the following (in thousands):

As of December 31, 2021 2020 Raw materials $ 135,528 $ 126,499 Work in process 36,490 33,053 Finished goods 118,217 155,376 Total $ 290,235 $ 314,928

Property, Plant and Equipment

Property, plant and equipment consists of the following (in thousands):

As of December 31, 2021 2020 Machinery and equipment $ 321,078 $ 291,331 Land, building and building improvements 243,377 241,199 Molds 60,463 60,381 Computer equipment and software 102,979 98,311 Furniture and fixtures 7,670 7,767 Instruments placed with customers (1)

97,384 90,383 Construction in progress 72,153 53,724 Total property, plant and equipment, cost 905,104 843,096 Accumulated depreciation (436,739) (376,468) Property, plant and equipment, net $ 468,365 $ 466,628


(1) Instruments placed with customers consist of drug-delivery and monitoring systems placed with customers under operating leases.

All property, plant and equipment are stated at cost.  We use the straight-line method for depreciating property, plant

Data imported from ICU Medical Inc. SEC filings. Check original filings before making any investment decision.